Detailed Information

Cited 38 time in webofscience Cited 40 time in scopus
Metadata Downloads

A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma

Authors
Woo, Hyun YoungBae, Si HyunPark, Jun YongHan, Kwang HyubChun, Ho JongChoi, Byung GilIm, Hyeon U.Choi, Jong YoungYoon, Seung KewCheong, Jae YounCho, Sung WonJang, Byoung KukHwang, Jae SeokKim, Sang GyuneKim, Young SeokSeo, Yeon SeokYim, Hyung JoonUm, Soon Ho
Issue Date
Jan-2010
Publisher
SPRINGER
Keywords
Hepatocellular carcinoma; Hepatic arterial infusion chemotherapy; High dose; Low dose; 5-Fluorouracil; Cisplatin
Citation
CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.65, no.2, pp.373 - 382
Indexed
SCIE
SCOPUS
Journal Title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume
65
Number
2
Start Page
373
End Page
382
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/15262
DOI
10.1007/s00280-009-1126-2
ISSN
0344-5704
Abstract
Hepatic arterial infusion chemotherapy (HAIC) has been reported to be effective in patients with advanced hepatocellular carcinoma (HCC). In this multicenter, prospective, open-labeled, clinical trial, we randomly assigned 68 patients with advanced HCC to receive either low-dose [n = 32, 5-fluorouracil (FU), 170 mg/m(2) and cisplatin, 7 mg/m(2) on days 1-5] or high-dose HAIC (n = 36, 5-FU, 500 mg/m(2) on days 1-3 and cisplatin, 60 mg/m(2) on day 2) every 4 weeks via an implantable port system. A total of 207 cycles of HAIC was given to the 68 patients. Overall, 6 patients (8.8%) achieved a partial response and 21 patients (30.9%) had stable disease. The objective response rate (CR + PR) was significantly improved in the high-dose group compared to the low-dose group (16.7% vs. 0%, P = 0.024). The median time to disease progression and overall survival were slightly prolonged in the high-dose group compared to the low-dose group (median survival, 193 vs. 153 days; P = 0.108; median time to disease progression, 145 vs. 90 days; P = 0.095). Multivariate analysis showed that tumor response to treatment [P = 0.007, RR 2.27 (95% CI, 1.248-4.132)] was the only factor associated with overall survival. All adverse events were tolerable and successfully managed in both treatment groups. Both HAIC regimens are safe and effective in patients with advanced HCC. High-dose HAIC achieves a better tumor response compared to low-dose HAIC.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yim, Hyung Joon photo

Yim, Hyung Joon
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE